Announced Mon, 10 Aug · 20:44 IST
Board Meeting on Aug 14 to consider Q1 FY26 financial results
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.9%1-day move
₹10.50
prior close
₹10.49
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.2+0.1+0.9+0.1+2.9+8.0+5.7+6.7+2.9-1.9+15.7+11.0——
Up moveDown movePending
AI summary
Nectar Lifesciences has informed the exchanges that its Board of Directors will meet on Friday, August 14, 2026, to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026 (Q1 FY26). No financial numbers have been shared in this filing. The notice is filed under SEBI listing regulations 29, 30 and 33 as a standard compliance disclosure.
Likely market impact
Routine advance notice. Actual Q1 earnings will be disclosed after the Aug 14 board meeting.